Biogen (1BIIB) Stock Forecast & Price Target
1BIIB Analyst Ratings
Moderate Buy
20Buy6Hold1Sell
Based on 27 analysts giving stock ratings to Biogen in the past 3 months
1BIIB Stock 12 Month Forecast
Average Price Target
EUR 237.35â–²(3.83% Upside)Based on 27 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is EUR 237.35 with a high forecast of EUR 291.00 and a low forecast of EUR 156.69. The average price target represents a 3.83% change from the last price of EUR 228.60.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 291.00
AverageEUR 237.35
LowEUR 156.69
Highest Price TargetHighestEUR 291.00Average Price TargetEUR 237.35Lowest Price TargetLowestEUR 156.69
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ananda Ghosh | H.C. Wainwright | EUR 224.74→EUR 241.76 | buy | 5.76%Upside | Reiterated | 11/02/26 | ||
| Yatin Suneja | Guggenheim | EUR 250.71→EUR 268.62 | buy | 17.51%Upside | Reiterated | 11/02/26 | ||
| Evan Seigerman | BMO Capital | EUR 223.85 | hold | -2.08%Downside | Reiterated | 11/02/26 | ||
| Jason Zemansky | Bank of America Securities | EUR 230.12 | hold | 0.66%Upside | Reiterated | 10/29/26 | ||
| Geoff Meacham | Citi | EUR 192.51→EUR 228.33 | hold | -0.12%Downside | Reiterated | 10/29/26 | ||
| Phil Nadeau | TD Cowen | EUR 223.85→EUR 232.80 | buy | 1.84%Upside | Reiterated | 10/29/26 | ||
| Mohit Bansal | Wells Fargo | EUR 277.57 | buy | 21.42%Upside | Reiterated | 10/29/26 | ||
| Brian Skorney | Robert W. Baird | EUR 223.85→EUR 259.67 | buy | 13.59%Upside | Reiterated | 10/29/26 | ||
| Ami Fadia | Needham | EUR 229.22→EUR 259.67 | buy | 13.59%Upside | Reiterated | 10/29/26 | ||
| Sumant Kulkarni | Canaccord Genuity | EUR 222.06→EUR 243.55 | buy | 6.54%Upside | Reiterated | 10/29/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | EUR 232.80 | buy | 1.84%Upside | Reiterated | 10/29/26 | ||
| Laura Chico | Wedbush | EUR 189.82→EUR 201.46 | hold | -11.87%Downside | Reiterated | 10/29/26 | ||
| Michael Yee | UBS | EUR 241.76→EUR 268.62 | buy | 17.51%Upside | Assigned | 10/29/26 | ||
| Terence Flynn | Morgan Stanley | EUR 213.10 | hold | -6.78%Downside | Reiterated | 10/29/26 | ||
| Jasper Hellweg | Argus Research | EUR 250.71 | buy | 9.67%Upside | Upgraded | 10/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ananda Ghosh | 11/02/26 | EUR 224.74→EUR 241.76 | buy | 5.76%Upside | Reiterated | H.C. Wainwright | ||
| Yatin Suneja | 11/02/26 | EUR 250.71→EUR 268.62 | buy | 17.51%Upside | Reiterated | Guggenheim | ||
| Evan Seigerman | 11/02/26 | EUR 223.85 | hold | -2.08%Downside | Reiterated | BMO Capital | ||
| Jason Zemansky | 10/29/26 | EUR 230.12 | hold | 0.66%Upside | Reiterated | Bank of America Securities | ||
| Geoff Meacham | 10/29/26 | EUR 192.51→EUR 228.33 | hold | -0.12%Downside | Reiterated | Citi | ||
| Phil Nadeau | 10/29/26 | EUR 223.85→EUR 232.80 | buy | 1.84%Upside | Reiterated | TD Cowen | ||
| Mohit Bansal | 10/29/26 | EUR 277.57 | buy | 21.42%Upside | Reiterated | Wells Fargo | ||
| Brian Skorney | 10/29/26 | EUR 223.85→EUR 259.67 | buy | 13.59%Upside | Reiterated | Robert W. Baird | ||
| Ami Fadia | 10/29/26 | EUR 229.22→EUR 259.67 | buy | 13.59%Upside | Reiterated | Needham | ||
| Sumant Kulkarni | 10/29/26 | EUR 222.06→EUR 243.55 | buy | 6.54%Upside | Reiterated | Canaccord Genuity | ||
| Unknown AnalystNot Ranked | 10/29/26 | EUR 232.80 | buy | 1.84%Upside | Reiterated | Leerink Partners | ||
| Laura Chico | 10/29/26 | EUR 189.82→EUR 201.46 | hold | -11.87%Downside | Reiterated | Wedbush | ||
| Michael Yee | 10/29/26 | EUR 241.76→EUR 268.62 | buy | 17.51%Upside | Assigned | UBS | ||
| Terence Flynn | 10/29/26 | EUR 213.10 | hold | -6.78%Downside | Reiterated | Morgan Stanley | ||
| Jasper Hellweg | 10/29/26 | EUR 250.71 | buy | 9.67%Upside | Upgraded | Argus Research |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Biogen
3 Months
Success Rate16/27 ratings generated profit
59%
Average Return
+2.08%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +2.08% per trade.
1 Year
Success Rate16/23 ratings generated profit
70%
Average Return
+22.65%
Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +22.65% per trade.
2 Years
Success Rate15/23 ratings generated profit
65%
Average Return
+26.63%
Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +26.63% per trade.
1BIIB Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 54 | 40 | 36 | 34 | 32 |
| Hold | 34 | 23 | 22 | 14 | 12 |
| Sell | 1 | 1 | 2 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 89 | 64 | 60 | 49 | 45 |
In the current month, 1BIIB has received 32 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. 1BIIB average Analyst price target in the past 3 months is 237.35.
1BIIB Financial Forecast
HighEUR 3.47
ConsensusEUR 2.56
LowEUR 2.19
1BIIB Earnings Forecast
Next quarter’s earnings estimate for 1BIIB is EUR 2.56 with a range of EUR 2.19 to EUR 3.47. The previous quarter’s EPS was EUR 2.35. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 3.02B
ConsensusEUR 2.33B
LowEUR 2.21B
1BIIB Sales Forecast
Next quarter’s sales forecast for 1BIIB is EUR 2.33B with a range of EUR 2.21B to EUR 3.02B. The previous quarter’s sales results were EUR 2.41B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1BIIB Stock Forecast FAQ
What is IT:1BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is €237.35.
What is IT:1BIIB’s upside potential, based on the analysts’ average price target?
Biogen has 3.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Biogen a Buy, Sell or Hold?
Biogen has a consensus rating of Moderate Buy, which is based on 20 buy ratings, 6 hold ratings and 1 sell ratings.
What is Biogen’s share price target?
The average share price target for Biogen is €237.35. This is based on 27 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €291.00, and the lowest forecast is €156.69. The average share price target represents a 3.83% increase from the current price of €228.6.
What do analysts say about Biogen?
Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Street analysts.
How can I buy shares of Biogen?
To buy shares of IT:1BIIB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
